Keybank National Association OH increased its holdings in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 30.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 71,383 shares of the biopharmaceutical company’s stock after buying an additional 16,569 shares during the quarter. Keybank National Association OH’s holdings in Royalty Pharma were worth $4,166,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in RPRX. Rakuten Investment Management Inc. bought a new position in shares of Royalty Pharma during the 3rd quarter valued at about $1,552,000. Monetta Financial Services Inc. acquired a new position in shares of Royalty Pharma in the 2nd quarter valued at approximately $1,682,000. Dorsey Asset Management LLC increased its stake in Royalty Pharma by 0.8% during the 1st quarter. Dorsey Asset Management LLC now owns 2,276,570 shares of the biopharmaceutical company’s stock worth $109,207,000 after purchasing an additional 17,101 shares in the last quarter. TD Waterhouse Canada Inc. increased its stake in Royalty Pharma by 121.2% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 81,697 shares of the biopharmaceutical company’s stock worth $4,564,000 after purchasing an additional 44,764 shares in the last quarter. Finally, NewEdge Advisors LLC increased its stake in Royalty Pharma by 400.2% during the 2nd quarter. NewEdge Advisors LLC now owns 21,597 shares of the biopharmaceutical company’s stock worth $1,211,000 after purchasing an additional 17,279 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors.
Royalty Pharma Price Performance
Shares of RPRX opened at $69.31 on Monday. The stock has a market capitalization of $39.76 billion, a P/E ratio of 57.76, a P/E/G ratio of 1.37 and a beta of 0.36. Royalty Pharma PLC has a twelve month low of $37.31 and a twelve month high of $70.37. The company has a 50 day moving average of $61.51 and a 200-day moving average of $54.53. The company has a quick ratio of 1.29, a current ratio of 1.29 and a debt-to-equity ratio of 0.77.
Royalty Pharma Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be issued a dividend of $0.2350 per share. The ex-dividend date is Friday, November 13th. This represents a $0.94 annualized dividend and a yield of 1.4%. Royalty Pharma’s dividend payout ratio is presently 78.33%.
Analyst Ratings Changes
Several analysts have commented on the stock. Weiss Ratings upgraded shares of Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday, September 14th. Bank of America reiterated a “buy” rating on shares of Royalty Pharma in a report on Wednesday, August 5th. TD Cowen increased their price objective on shares of Royalty Pharma from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Tuesday, September 8th. Wall Street Zen raised shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Finally, Morgan Stanley upped their target price on shares of Royalty Pharma from $65.00 to $67.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. One analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company. According to data from MarketBeat.com, Royalty Pharma currently has an average rating of “Buy” and a consensus price target of $63.29.
Check Out Our Latest Stock Analysis on RPRX
Insiders Place Their Bets
In other news, EVP Marshall Urist sold 4,126 shares of the firm’s stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $57.10, for a total value of $235,594.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 100,000 shares of Royalty Pharma stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $58.53, for a total value of $5,853,000.00. Following the completion of the sale, the executive vice president directly owned 270,401 shares in the company, valued at approximately $15,826,570.53. This represents a 27.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 208,252 shares of company stock valued at $12,324,407. 18.84% of the stock is owned by insiders.
Royalty Pharma Company Profile
Royalty Pharma plc is a biopharmaceutical royalty company that provides funding to companies and inventors in exchange for royalty interests in medicines. It acquires existing royalties and helps finance drug development and commercialization through royalty-based transactions and other forms of funding. The company’s portfolio includes royalty interests in medicines across a range of therapeutic areas, spanning both approved treatments and products in development. Royalty Pharma generally earns revenue when these medicines are sold; it does not operate as a conventional drug manufacturer or commercialize medicines itself.
Featured Stories
- Five stocks we like better than Royalty Pharma
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding RPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Royalty Pharma PLC (NASDAQ:RPRX – Free Report).
Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
